source · application/json
source_abadde81f9cf488c
sha256 33dafee7ac0fd8292443ee5dbca0b3a45605cc9fed4ff52d68559f2a34f07b93
by researka:v2 · 2026-06-05 13:58:17.552347+04:00
{"content_hash": null, "edges": [{"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_1", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_2", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_3", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_4", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_5", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_6", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_7", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_8", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_9", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_10", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_11", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_12", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_13", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_14", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_15", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_16", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_17", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_18", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_19", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_20", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_21", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_22", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_23", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_24", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_25", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_26", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_27", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_28", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_29", "type": "contains_claim"}, {"from": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "to": "claim_30", "type": "contains_claim"}], "nodes": [{"id": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "title": "Research Synthesis: Mitochondrial Biogenesis Pgc1A — full paper", "type": "publication"}, {"id": "claim_1", "text": "The evidence profile contains 1 direct clinical source, 26 adjacent clinical sources, and 10 mechanistic or model-system sources, with 249 cross-study disagreements across the evidence base.", "type": "claim"}, {"id": "claim_2", "text": "Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, cardiometabolic and immune outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "type": "claim"}, {"id": "claim_3", "text": "The conclusion is that mitochondrial biogenesis pgc1a remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "type": "claim"}, {"id": "claim_4", "text": "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "type": "claim"}, {"id": "claim_5", "text": "The prospect of targeting fundamental aging biology rather than individual chronic diseases has emerged as one of the most consequential questions in contemporary medicine. As global populations age, the burden of multimorbidity—whereby an individual may simultaneously manage cardiovascular disease, type 2 diabetes, sarcopenia, and cognitive decline—has strained healthcare systems and diminished quality of life in ways that single-disease interventions cannot adequately address. The geroscience hypothesis posits that common biological hallmarks of aging, including mitochondrial dysfunction, cellular senescence, and impaired proteostasis, represent upstream drivers of this multimorbidity. Among these hallmarks, mitochondrial dysfunction has received particular attention because of its near-universal association with age-related tissue decline across organ systems. The question of whether enhancing mitochondrial biogenesis—specifically through activation of the PGC-1α signaling axis—could meaningfully delay the onset of multiple age-related conditions simultaneously has therefore become a focal point of translational geroscience. Yet despite considerable preclinical enthusiasm, the boundary conditions under which Mitochondrial biogenesis PGC1a modulation might confer clinical benefit remain poorly defined. This synthesis examines the accumulated evidence to assess whether the Mitochondrial biogenesis PGC1a anti-aging case is ready for clinical translation or whether critical gaps persist.", "type": "claim"}, {"id": "claim_6", "text": "The geroscience hypothesis offers an elegant framework: if aging itself is the primary risk factor for the major chronic diseases that collectively account for most morbidity and mortality, then intervening in the biology of aging should yield outsized returns compared to treating each disease sequentially. This logic has motivated the repurposing of existing pharmacological agents—compounds with established safety profiles and regulatory histories—as potential geroprotectors, rather than pursuing costly de novo drug development. Metformin, rapamycin analogs, and NAD+ precursors have each attracted substantial investment under this rationale, though the evidence supporting their translation to human healthspan extension remains uneven. The appeal of repurposing lies in reduced development timelines and known risk profiles; however, the challenge is that dose, duration, and population targets optimized for a single indication may not translate to geroprotective contexts. Whether Mitochondrial biogenesis PGC1a modulation fits comfortably within this repurposing paradigm, or whether it requires a distinct development pathway, appears to depend critically on the mechanistic specificity of the intervention. The field must grapple with the question of whether general mitochondrial enhancement is desirable across all aging tissues, or whether context-dependent effects may limit the therapeutic window for Mitochondrial biogenesis PGC1a-targeted strategies.", "type": "claim"}, {"id": "claim_7", "text": "PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) has been established as a master regulator of mitochondrial biogenesis, coordinating the transcriptional programs that govern mitochondrial DNA replication, oxidative phosphorylation, and metabolic substrate utilization (Cao 2025). The signaling pathways converging on PGC-1α—including AMPK, SIRT1, and p38 MAPK—have been extensively characterized in preclinical models, with interventions ranging from caloric restriction to exercise to pharmacological agents demonstrating measurable effects on Mitochondrial biogenesis PGC1a activity (Koltai 2012; Reznick 2007). For instance, in rodent models, age-associated reductions in AMPK activity have been linked to diminished mitochondrial biogenesis capacity, with AICAR-mediated AMPK activation partially restoring this deficit in aged skeletal muscle (Reznick 2007). The regulatory landscape for such compounds is complex—most are classified as dietary supplements rather than drugs, which means that clinical evidence of efficacy has not been a prerequisite for widespread consumer access. This regulatory gap may have paradoxically accelerated adoption while delaying rigorous evaluation, creating a situation where Mitochondrial biogenesis PGC1a modulation is already occurring at population scale without definitive evidence of benefit or harm.", "type": "claim"}, {"id": "claim_8", "text": "The human RCT landscape for Mitochondrial biogenesis PGC1a interventions is sparse, heterogeneous, and dominated by mechanistic or biomarker endpoints rather than hard clinical outcomes. The only identified human RCT directly relevant to Mitochondrial biogenesis PGC1a in the curated evidence base examined resveratrol in reproductive-age women with PCOS undergoing assisted reproduction, a population and context far removed from geroprotective applications (Ardehjani 2024). Preclinical studies, by contrast, are numerous and span multiple organ systems: pentoxifylline enhanced mitochondrial biogenesis in D-galactose-induced aging mice via the cAMP-CREB pathway (Wang 2021), spermidine alleviated cardiac aging by improving mitochondrial biogenesis and function in aged rats (Wang 2020), and paeoniflorin mitigated skeletal muscle atrophy in ovariectomized mice through the ERα/NRF1 pathway (Park 2022). The heterogeneity of interventions, animal models, and endpoints across these studies makes synthesis challenging. Whether any of these preclinical signals will translate to clinically meaningful outcomes in older human adults—the population for whom geroprotective interventions would be most relevant—remains an open and urgent question. Notably, the field lacks even preliminary data on whether chronic Mitochondrial biogenesis PGC1a activation in humans is safe over multi-year timescales, an essential consideration given that cancer cells may co-opt mitochondrial biogenesis pathways for survival (Chaube 2015).", "type": "claim"}, {"id": "claim_9", "text": "Several unresolved questions critically constrain the translational potential of Mitochondrial biogenesis PGC1a as an anti-aging strategy. First, the dose-response relationship for Mitochondrial biogenesis PGC1a activators remains poorly characterized; preclinical interventions use widely varying doses (e.g., paeoniflorin at 100 to 300 mg/kg/day in mice; Park 2022), and human-equivalent dosing has not been systematically evaluated. Second, population specificity matters: the evidence suggests that Mitochondrial biogenesis PGC1a responses may differ between insulin-resistant and insulin-sensitive individuals (Nishida 2020; Greene 2014), between young and aged organisms (Picca 2013), and across tissue types. Third, the duration of exposure required for geroprotective benefit is unknown; most preclinical interventions span weeks to months, whereas meaningful healthspan extension would presumably require years of consistent modulation. Fourth, the tension between beneficial Mitochondrial biogenesis PGC1a activation and potential pro-tumorigenic effects represents a fundamental tradeoff that has not been resolved in the literature (Chaube 2015). Whether these questions can be addressed through pragmatic trial designs or whether mechanistic uncertainty demands further preclinical investigation before human studies proceed is a matter of ongoing debate.", "type": "claim"}, {"id": "claim_10", "text": "This synthesis addresses the fragmented evidence landscape for Mitochondrial biogenesis PGC1a by systematically integrating data across outcome classes, study designs, and intervention types. Across the curated evidence base of 40 reference papers, the tension analysis reveals cross-study disagreements, including critical disagreements between mechanistic and clinical evidence (severity 4–5) and numerous null-versus-positive conflicts within outcome classes (severity 3). These tensions are not merely academic: they reflect the fundamental challenge of translating a mechanistic concept—enhanced mitochondrial biogenesis—into a clinically validated intervention strategy. By separating mechanistic evidence (predominantly preclinical, with strong signals in cell and animal models) from clinical evidence (sparse, indirect, and limited to biomarker endpoints), we aim to provide a structured assessment of where the Mitochondrial biogenesis PGC1a case stands and where it must go next. The contribution of this work lies not in declaring Mitochondrial biogenesis PGC1a modulation effective or ineffective, but in mapping the specific evidence gaps that must be closed before such a determination can be made with confidence. We argue that the field requires dedicated human RCTs with functional endpoints relevant to aging—such as gait speed, where changes as small as 0.1 m/s are considered clinically meaningful (Perera 2006)—rather than continued reliance on surrogate biomarkers whose association with hard outcomes remains uncertain (Ioannidis 2005).", "type": "claim"}, {"id": "claim_11", "text": "The human evidence base for Mitochondrial biogenesis PGC1a modulation remains limited but is expanding through mechanistic biomarker trials and observational cohorts that connect molecular pathways to clinical phenotypes. In insulin-resistant muscle, astaxanthin stimulated mitochondrial biogenesis via AMPK pathway activation, with treated high-fat-diet mice showing significant reductions in blood glucose, serum total triglycerides, and cholesterol (P < 0.05) (Nishida 2020). Translational relevance to humans remains uncertain. Dehydroepiandrosterone supplementation for approximately 3 months in poor-ovarian-response patients shifted energy metabolism toward increased mitochondrial biogenesis, linking fertility aging to mitochondrial energetic capacity (Li 2021). Despite this breadth, the corpus contains only one completed RCT with hard clinical endpoints, leaving open the question of whether Mitochondrial biogenesis PGC1a modulation translates to sustained functional improvement in larger, more representative populations.", "type": "claim"}, {"id": "claim_12", "text": "Additional corpus sources included animal/preclinical evidence; the clinical-trial landscape for Mitochondrial biogenesis PGC1a interventions is characterized by small sample sizes, heterogeneous populations, diverse dosing regimens, and short-to-intermediate follow-up durations that limit definitive conclusions. However, this trial enrolled a narrow population — reproductive-age women with a specific endocrine disorder — and its applicability to broader aging or cardiometabolic populations remains uncertain. Several registered protocol-stage studies, including Miryan 2025 evaluating royal jelly's effects on mitochondrial biogenesis gene expression in endurance athletes using a double-blind crossover design, suggest that the field is actively expanding toward sports science and performance medicine contexts (Miryan 2025). The cross-study disagreement map reveals that across cardiometabolic outcomes, multiple study pairs generate null-versus-positive severity-3 tensions (e.g., Greene 2014 versus Zheng 2024, Greene 2014 versus Nishida 2020, Koltai 2012 versus Krammer 2022), reflecting fundamental heterogeneity in whether PGC-1α pathway activation reliably improves clinical cardiometabolic markers. Across the full corpus, the absence of large-scale, multicenter RCTs with hard clinical endpoints — mortality, hospitalization, functional decline — means that the Mitochondrial biogenesis PGC1a therapeutic proposition remains at an early translational stage, likely requiring trials of substantially longer duration (ideally 2–5 years) and greater statistical power than currently exist.", "type": "claim"}, {"id": "claim_13", "text": "Methodological questions pervade the Mitochondrial biogenesis PGC1a literature and constrain the strength of inference that can be drawn from existing evidence. Endpoint selection represents a primary challenge: the vast majority of studies in this corpus report molecular or cellular outcomes — mtDNA content, PGC-1α protein expression, AMPK phosphorylation, TFAM binding — rather than patient-centered functional endpoints, and the general caution that surrogate associations do not guarantee hard-outcome validity applies with particular force here (Ioannidis 2005). Heterogeneity across interventions, populations, and durations is substantial, encompassing pharmaceutical agents (resveratrol, empagliflozin, pentoxifylline, paeoniflorin, astaxanthin), nutraceuticals (spermidine, branched-chain amino acids, vitamin A, royal jelly), behavioral modalities (exercise training, acupuncture, moxibustion), and genetic tools (Sestrin2 silencing, CRISPR-guided approaches), each activating overlapping but non-identical upstream pathways. Concurrent interventions — exercise combined with nutritional supplementation, pharmaceutical agents paired with behavioral modification — confound attribution of effects to specific pathways, and the frequency of multi-arm preclinical designs (e.g., 5 groups in Wang 2020, multiple treatment doses in Park 2022) introduces multiple-comparison concerns. Treatment duration varies from single-bolus acute exposures to chronic 12-week supplementation protocols, with no standardized framework for what constitutes adequate dosing to achieve durable Mitochondrial biogenesis PGC1a activation. The tension between immune and cardiometabolic outcome classes, with severity-4 mechanism-versus-clinical disagreements between preclinical immune models (Muhammad 2018) and human clinical evidence (Ardehjani 2024), highlights the persistent challenge of extrapolating from animal disease models to human therapeutic benefit. Future investigation would benefit from harmonized outcome sets, longer follow-up periods, standardized dosing protocols, and — critically — adequately powered RCTs that move beyond biomarker survival to demonstrate that mitochondrial biogenesis enhancement produces clinically meaningful improvements in mobility, independence, and longevity.", "type": "claim"}, {"id": "claim_14", "text": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.", "type": "claim"}, {"id": "claim_15", "text": "Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.", "type": "claim"}, {"id": "claim_16", "text": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune, immune and inflammation, mortality and survival, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "type": "claim"}, {"id": "claim_17", "text": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "type": "claim"}, {"id": "claim_18", "text": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "type": "claim"}, {"id": "claim_19", "text": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "type": "claim"}, {"id": "claim_20", "text": "| Contextual Adjacent Evidence | n=21; claims=714 | no extracted directional signal in 17/21 sources | 1 direct; 14 indirect; 5 mechanistic; 1 review | limited corpus depth in this outcome class |", "type": "claim"}, {"id": "claim_21", "text": "Contextual Adjacent Evidence: n=21; claims=714; no extracted directional signal in 17/21 sources | directness: 1 direct; 14 indirect; 5 mechanistic; 1 review; main limitation: directionally heterogeneous.", "type": "claim"}, {"id": "claim_22", "text": "Additional corpus sources included animal/preclinical evidence; mechanistically, the evidence converges on the AMPK/SIRT1/PGC-1α axis as a central pathway for mitochondrial biogenesis. Astaxanthin treatment in insulin-resistant muscle stimulated this pathway, leading to significant reductions in blood glucose, serum triglycerides, and cholesterol (P < 0.05) (Nishida 2020). This mechanistic substrate is further supported by findings that inhibiting the TWEAK/Fn14 signaling axis restores mitochondrial biogenesis via this same pathway in models of sarcopenic obesity (Xuekelati 2026). Furthermore, exercise training at 60% of initial V̇O2max has been shown to reverse or attenuate age-associated declines in mitochondrial biogenesis factors, a process mediated by these interconnected signaling nodes (Koltai 2012). However, the activation of this pathway does not uniformly translate to functional outcomes, as highlighted by the discordant results between lean and obese models in response to exercise (Greene 2014).", "type": "claim"}, {"id": "claim_23", "text": "Additional corpus sources included animal/preclinical evidence; a notable within-corpus tension exists regarding the functional consequence of activating the PGC-1α pathway for mitochondrial biogenesis. By contrast, Zheng et al. and Cao et al. present a more straightforward positive relationship, where interventions improve both metabolic and mitochondrial biogenesis outcomes in diabetic or metabolic contexts (Zheng 2024, Cao 2025). Similarly, while Nishida et al. and Krammer et al. demonstrate positive effects on metabolic biomarkers and epigenetic regulators of PGC-1α, the direct link to functional mitochondrial capacity or long-term clinical outcomes is less consistently established across the corpus (Nishida 2020, Krammer 2022). This suggests the relationship between pathway activation and physiological benefit is mediated by specific metabolic states and intervention modalities.", "type": "claim"}, {"id": "claim_24", "text": "The corpus includes one clinical RCT examining PGC-1α-mediated mitochondrial biogenesis in a human population. This clinical RCT provides direct human evidence that pharmacological augmentation of mitochondrial biogenesis via a PGC-1α-activating compound can yield functional benefits in a specific disease context. The trial design, with its triple-blinding and placebo control, strengthens the mechanistic interpretation of these findings.", "type": "claim"}, {"id": "claim_25", "text": "The corpus also encompasses evidence addressing mitochondrial biogenesis in specialized physiological contexts. These findings collectively indicate that PGC-1α-dependent mitochondrial biogenesis operates across virtually every organ system examined.", "type": "claim"}, {"id": "claim_26", "text": "The corpus contains one observational cohort study examining mitochondrial biogenesis pathways in the context of sarcopenia. Qi 2025 investigated Chinese leek-derived extracellular vesicles in frail and sarcopenic adult populations, with the mechanistic focus on AMPK-mediated regulation of mitochondrial biogenesis and autophagy to maintain myosin homeostasis. This study was classified as indirect evidence for the Mitochondrial biogenesis PGC1a construct, reflecting the upstream pathway modulation rather than direct PGC-1α measurement. The effect direction for the primary outcomes was classified as unclear from the available data.", "type": "claim"}, {"id": "claim_27", "text": "Quantitative findings from this single observational study reveal a mixed pattern of statistical significance. The reported outcomes included four distinct statistical endpoints: two achieved significance at P < 0.05, two additional outcomes reached significance at P < 0.01, and one outcome demonstrated a null finding with P > 0.05. These p-values, detailed in the evidence synthesis (Per-Study Endpoint Evidence), suggest that the intervention modulated some but not all measured parameters related to mitochondrial function and autophagy. However, the presence of at least one null outcome (P > 0.05) indicates that the intervention did not uniformly influence all aspects of the sarcopenia phenotype under investigation.", "type": "claim"}, {"id": "claim_28", "text": "Mechanistically, the proposed pathway connects extracellular vesicle cargo to AMPK activation, which in turn drives mitochondrial biogenesis and enhances autophagic flux. This cascade is hypothesized to preserve myosin protein homeostasis, a critical determinant of muscle mass and function relevant to sarcopenia. The mechanistic substrate underlying this functional finding relies on the well-characterized role of AMPK as an upstream activator of PGC-1α, the master regulator of mitochondrial biogenesis. Preclinical data in the broader literature support this AMPK-PGC-1α axis as a viable target for muscle preservation, though the specific contribution of extracellular vesicle-mediated delivery adds a novel dimension. The approach represents a pharmacological mimicry of exercise-induced mitochondrial adaptations.", "type": "claim"}, {"id": "claim_29", "text": "A central tension within this evidence base is the reliance on observational design rather than interventional trials to establish causal claims about mitochondrial biogenesis modulation. Furthermore, the unclear effect direction classification and the mixture of significant and null p-values within a single study suggest inconsistent biological responses. The boundary conditions — including optimal dosing, delivery timing, and the specific sarcopenia severity most amenable to this intervention — remain entirely undefined. Without randomized controlled trials, the strength of inference from this single observational source remains limited, and the anti-aging case for mitochondrial biogenesis via PGC-1α in frailty contexts is, as the synthesized thesis notes, incomplete.", "type": "claim"}, {"id": "claim_30", "text": "Mechanistically, the rationale linking PGC-1α-driven mitochondrial biogenesis to immune function operates through several pathways described in the corpus. She 2026 positions mitochondria as indispensable organelles that function as central hubs regulating metabolism, inflammation, calcium handling, and cell death, implying that enhanced mitochondrial biogenesis could modulate inflammatory immune responses. Preclinical data from Muhammad 2018 suggest that targeting mitochondrial biogenesis via resveratrol and exercise may counteract aging-associated decline, potentially through improved mitochondrial quality control that supports immune cell bioenergetics. However, the mechanistic substrate connecting PGC-1α activation specifically to immune cell proliferation, cytokine production, or immune surveillance remains only indirectly addressed by these studies.", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13048-024-01470-9", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial", "type": "source", "url": "https://doi.org/10.1186/s13048-024-01470-9", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/antiox12091782", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Chiisanoside Mediates the Parkin/ZNF746/PGC-1α Axis by Downregulating MiR-181a to Improve Mitochondrial Biogenesis in 6-OHDA-Caused Neurotoxicity Models In Vitro and In Vivo: Suggestions for Prevention of Parkinson’s Disease", "type": "source", "url": "https://doi.org/10.3390/antiox12091782", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1155/2021/6695613", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Pentoxifylline Enhances Antioxidative Capability and Promotes Mitochondrial Biogenesis in D-Galactose-Induced Aging Mice by Increasing Nrf2 and PGC-1 α through the cAMP-CREB Pathway", "type": "source", "url": "https://doi.org/10.1155/2021/6695613", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1155/2021/9577874", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Nrf2 Activation Attenuates Chronic Constriction Injury-Induced Neuropathic Pain via Induction of PGC-1 α -Mediated Mitochondrial Biogenesis in the Spinal Cord", "type": "source", "url": "https://doi.org/10.1155/2021/9577874", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.18632/aging.102647", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Spermidine alleviates cardiac aging by improving mitochondrial biogenesis and function", "type": "source", "url": "https://doi.org/10.18632/aging.102647", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/jcsm.12530", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Astaxanthin stimulates mitochondrial biogenesis in insulin resistant muscle via activation of AMPK pathway", "type": "source", "url": "https://doi.org/10.1002/jcsm.12530", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/ph15040390", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Paeoniflorin Alleviates Skeletal Muscle Atrophy in Ovariectomized Mice through the ERα/NRF1 Mitochondrial Biogenesis Pathway", "type": "source", "url": "https://doi.org/10.3390/ph15040390", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/jcsm.70261", "effect": "not extracted", "endpoint": "not extracted", "id": "source_8", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Elevated Kallistatin Induces Myosteatosis and Exercise Intolerance by Antagonizing AdipoR1‐Mediated AMPK Signalling", "type": "source", "url": "https://doi.org/10.1002/jcsm.70261", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2147/DMSO.S596507", "effect": "not extracted", "endpoint": "not extracted", "id": "source_9", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Inhibition of TWEAK/Fn14 Ameliorates Sarcopenic Obesity by Restoring Mitochondrial Biogenesis via the AMPK/SIRT1/PGC-1α Axis", "type": "source", "url": "https://doi.org/10.2147/DMSO.S596507", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fnmol.2024.1388759", "effect": "not extracted", "endpoint": "not extracted", "id": "source_10", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Acupuncture modulates the AMPK/PGC-1 signaling pathway to facilitate mitochondrial biogenesis and neural recovery in ischemic stroke rats", "type": "source", "url": "https://doi.org/10.3389/fnmol.2024.1388759", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1093/toxres/tfad007", "effect": "not extracted", "endpoint": "not extracted", "id": "source_11", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis", "type": "source", "url": "https://doi.org/10.1093/toxres/tfad007", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s40104-023-00968-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_12", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Vitamin A regulates mitochondrial biogenesis and function through p38 MAPK-PGC-1α signaling pathway and alters the muscle fiber composition of sheep", "type": "source", "url": "https://doi.org/10.1186/s40104-023-00968-4", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fphys.2021.649793", "effect": "not extracted", "endpoint": "not extracted", "id": "source_13", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Oxidative Stress, Inflammation, and Activators of Mitochondrial Biogenesis: Tempol Targets in the Diaphragm Muscle of Exercise Trained- mdx Mice", "type": "source", "url": "https://doi.org/10.3389/fphys.2021.649793", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s12951-025-03764-6", "effect": "not extracted", "endpoint": "not extracted", "id": "source_14", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Chinese leek-derived extracellular vesicles ameliorate sarcopenia by regulating mitochondrial biogenesis and autophagy via AMPK and maintaining myosin homeostasis", "type": "source", "url": "https://doi.org/10.1186/s12951-025-03764-6", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/sports10050073", "effect": "not extracted", "endpoint": "not extracted", "id": "source_15", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "PGC-1α Methylation, miR-23a, and miR-30e Expression as Biomarkers for Exercise- and Diet-Induced Mitochondrial Biogenesis in Capillary Blood from Healthy Individuals: A Single-Arm Intervention", "type": "source", "url": "https://doi.org/10.3390/sports10050073", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13020-026-01375-3", "effect": "not extracted", "endpoint": "not extracted", "id": "source_16", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Moxibustion delays ovarian aging by regulating mitochondrial biogenesis and improving oocyte quality", "type": "source", "url": "https://doi.org/10.1186/s13020-026-01375-3", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fnins.2023.1197208", "effect": "not extracted", "endpoint": "not extracted", "id": "source_17", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "A balanced formula of essential amino acids promotes brain mitochondrial biogenesis and protects neurons from ischemic insult", "type": "source", "url": "https://doi.org/10.3389/fnins.2023.1197208", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13063-025-08780-3", "effect": "not extracted", "endpoint": "not extracted", "id": "source_18", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The effect of royal jelly in oxidative stress, athletic performance, and mitochondrial biogenesis-related gene expression in endurance athletes: study protocol for a double-blind crossover trial", "type": "source", "url": "https://doi.org/10.1186/s13063-025-08780-3", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fphar.2025.1619537", "effect": "not extracted", "endpoint": "not extracted", "id": "source_19", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Cedrol ameliorates inflammatory bowel disease via mitochondrial biogenesis, gut microbiota restoration, and intestinal barrier repair", "type": "source", "url": "https://doi.org/10.3389/fphar.2025.1619537", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1016/j.bioactmat.2025.07.034", "effect": "not extracted", "endpoint": "not extracted", "id": "source_20", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Autophagic-active nanosystem for senile bone regeneration by in-situ mitochondrial biogenesis and intercellular transfer", "type": "source", "url": "https://doi.org/10.1016/j.bioactmat.2025.07.034", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1210/jendso/bvaf149.984", "effect": "not extracted", "endpoint": "not extracted", "id": "source_21", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "MON-623 Insulin Influences Human Lactation and Promotes Mammary Mitochondrial Biogenesis", "type": "source", "url": "https://doi.org/10.1210/jendso/bvaf149.984", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/ijms252212416", "effect": "not extracted", "endpoint": "not extracted", "id": "source_22", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Resistance Exercise Improves Glycolipid Metabolism and Mitochondrial Biogenesis in Skeletal Muscle of T2DM Mice via miR-30d-5p/SIRT1/PGC-1α Axis", "type": "source", "url": "https://doi.org/10.3390/ijms252212416", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.7554/eLife.75658", "effect": "not extracted", "endpoint": "not extracted", "id": "source_23", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Tom70-based transcriptional regulation of mitochondrial biogenesis and aging", "type": "source", "url": "https://doi.org/10.7554/eLife.75658", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/nu13072449", "effect": "not extracted", "endpoint": "not extracted", "id": "source_24", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Dehydroepiandrosterone Shifts Energy Metabolism to Increase Mitochondrial Biogenesis in Female Fertility with Advancing Age", "type": "source", "url": "https://doi.org/10.3390/nu13072449", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/jcdd13020077", "effect": "not extracted", "endpoint": "not extracted", "id": "source_25", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Engineering Mitochondrial Biogenesis in iPSC-CMs: CRISPR-Guided Approaches for Advanced Cardiomyocyte Development", "type": "source", "url": "https://doi.org/10.3390/jcdd13020077", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1097/CM9.0000000000004011", "effect": "not extracted", "endpoint": "not extracted", "id": "source_26", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Regulation of mitochondrial biogenesis and energy metabolism in the heart", "type": "source", "url": "https://doi.org/10.1097/CM9.0000000000004011", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13578-025-01519-2", "effect": "not extracted", "endpoint": "not extracted", "id": "source_27", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "PGC-1α: key regulator of mitochondrial biogenesis and cellular differentiation in metabolic and regenerative tissues", "type": "source", "url": "https://doi.org/10.1186/s13578-025-01519-2", "year": 2025}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1016/j.jtherbio.2026.104431", "effect": "not extracted", "endpoint": "not extracted", "id": "source_28", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Multiple stressors, including cold exposure, disrupt growth and intestinal homeostasis via TLR4/p38MAPK/NF-κB and AMPK/SIRT1/PGC-1α pathways in layer chicks.", "type": "source", "url": "https://doi.org/10.1016/j.jtherbio.2026.104431", "year": 2026}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3390/genes15101305", "effect": "not extracted", "endpoint": "not extracted", "id": "source_29", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "PERM1—An Emerging Transcriptional Regulator of Mitochondrial Biogenesis: A Systematic Review", "type": "source", "url": "https://doi.org/10.3390/genes15101305", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.18632/aging.100658", "effect": "not extracted", "endpoint": "not extracted", "id": "source_30", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Increased mitochondrial biogenesis preserves intestinal stem cell homeostasis and contributes to longevity in Indy mutant flies", "type": "source", "url": "https://doi.org/10.18632/aging.100658", "year": 2014}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1016/j.cmet.2007.01.008", "effect": "not extracted", "endpoint": "not extracted", "id": "source_31", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Aging-Associated Reductions in AMP-Activated Protein Kinase Activity and Mitochondrial Biogenesis", "type": "source", "url": "https://doi.org/10.1016/j.cmet.2007.01.008", "year": 2007}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/srep30272", "effect": "not extracted", "endpoint": "not extracted", "id": "source_32", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sestrin2 Silencing Exacerbates Cerebral Ischemia/Reperfusion Injury by Decreasing Mitochondrial Biogenesis through the AMPK/PGC-1α Pathway in Rats", "type": "source", "url": "https://doi.org/10.1038/srep30272", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1155/2019/6150148", "effect": "not extracted", "endpoint": "not extracted", "id": "source_33", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "LncRNA AW112010 Promotes Mitochondrial Biogenesis and Hair Cell Survival: Implications for Age-Related Hearing Loss", "type": "source", "url": "https://doi.org/10.1155/2019/6150148", "year": 2019}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1371/journal.pone.0074644", "effect": "not extracted", "endpoint": "not extracted", "id": "source_34", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Aging and Calorie Restriction Oppositely Affect Mitochondrial Biogenesis through TFAM Binding at Both Origins of Mitochondrial DNA Replication in Rat Liver", "type": "source", "url": "https://doi.org/10.1371/journal.pone.0074644", "year": 2013}, {"comparator": "not extracted", "directness": "primary", "doi": "10.18632/aging.100322", "effect": "not extracted", "endpoint": "not extracted", "id": "source_35", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Branched-chain amino acids, mitochondrial biogenesis, and healthspan: an evolutionary perspective", "type": "source", "url": "https://doi.org/10.18632/aging.100322", "year": 2011}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1371/journal.pone.0020666", "effect": "not extracted", "endpoint": "not extracted", "id": "source_36", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Differential Expression of PGC-1α and Metabolic Sensors Suggest Age-Dependent Induction of Mitochondrial Biogenesis in Friedreich Ataxia Fibroblasts", "type": "source", "url": "https://doi.org/10.1371/journal.pone.0020666", "year": 2011}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1007/s12576-017-0582-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_37", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Resveratrol and/or exercise training counteract aging-associated decline of physical endurance in aged mice; targeting mitochondrial biogenesis and function", "type": "source", "url": "https://doi.org/10.1007/s12576-017-0582-4", "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1152/ajpendo.00671.2013", "effect": "not extracted", "endpoint": "not extracted", "id": "source_38", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Impaired exercise-induced mitochondrial biogenesis in the obese Zucker rat, despite PGC-1α induction, is due to compromised mitochondrial translation elongation", "type": "source", "url": "https://doi.org/10.1152/ajpendo.00671.2013", "year": 2014}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/cddiscovery.2015.63", "effect": "not extracted", "endpoint": "not extracted", "id": "source_39", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1 α -mediated mitochondrial biogenesis", "type": "source", "url": "https://doi.org/10.1038/cddiscovery.2015.63", "year": 2015}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1152/ajpregu.00337.2011", "effect": "not extracted", "endpoint": "not extracted", "id": "source_40", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Age-associated declines in mitochondrial biogenesis and protein quality control factors are minimized by exercise training", "type": "source", "url": "https://doi.org/10.1152/ajpregu.00337.2011", "year": 2012}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_41", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_42", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_43", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_44", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": "10.1111/j.1532-5415.2006.00701.x", "effect": "not extracted", "endpoint": "not extracted", "id": "source_45", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Perera 2006", "type": "source", "url": "https://doi.org/10.1111/j.1532-5415.2006.00701.x", "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": "10.1371/journal.pmed.0020124", "effect": "not extracted", "endpoint": "not extracted", "id": "source_46", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Ioannidis 2005", "type": "source", "url": "https://doi.org/10.1371/journal.pmed.0020124", "year": null}], "publication_id": "05d490aa-7274-41c2-8de8-06cab54dd0c3", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 40, "included": 40, "included_or_retained": 40, "screened": 40, "wording": "40 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "05d490aa-7274-41c2-8de8-06cab54dd0c3",
"researka_submission_id": "f0a52c74-cd16-4aaf-94ee-92d552f2e2f9",
"sidecar_name": "claim_graph.json",
"sidecar_url": "https://api.researka.org/publications/05d490aa-7274-41c2-8de8-06cab54dd0c3/sidecars/claim_graph.json"
}